OrthoPediatrics Corp.

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

OrthoPediatrics reported record Q3 2026 revenue of $72.7 million, up 19% year-over-year, helped nearly 42,000 children, and posted record adjusted EBITDA of $6.9 million. Net loss narrowed to $5.9 million ($0.25 per share) from $11.8 million a year ago, and free cash flow turned positive at $1.6 million, a $5.0 million improvement versus prior-year usage. The company raised full-year 2026 revenue guidance to $270.0-$273.0 million from $265.0-$269.0 million (14-16% growth), reiterated ~$25.0 million adjusted EBITDA expectations, and targeted breakeven annual free cash flow. Growth was broad-based: Trauma & Deformity up 19% and Scoliosis up 18%, alongside a full market release of the 3P Hip System and new product launches including FDA-cleared PNP Retrograde.

•12d ago

OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations

OrthoPediatrics received FDA 510(k) clearance for the PNP | Femur Retrograde Nail System and has already completed the first implantations. The system was designed specifically for pediatric anatomy, offering anatomic nails for trauma and straight nails for deformity, and leverages existing PNP instrumentation. Availability begins via limited market release through the rest of 2026, with broader commercialization planned for 2027. The Pediatric Nailing Platform has supported nearly 15,000 patients worldwide to date.

•12d ago

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

OrthoPediatrics launched the OPSB Knee 'TractorFIX contracture management orthosis, a first-of-its-kind pediatric brace for knee contractures in patients roughly 2 to 21 undergoing tibial treatment with an external fixator. The brace connects directly to the external fixator and pairs with the company's ORTHEX External Fixation platform, addressing an unmet clinical need where providers previously relied on custom-built solutions. The launch expands the OPSB lower extremity bracing portfolio alongside DF2, TRAXIO, and PediHip, supporting the company's broader pediatric orthopedics innovation pipeline; no financial terms were disclosed.

•1mo ago

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations

OrthoPediatrics surpassed 1,000 implantations of its PNP Tibia Nail, part of the Pediatric Nailing Platform purpose-built to enable rigid tibial nailing in pediatric patients. The company's 7mm cannulated rigid tibial nail is the only product of its size, and nearly 20% of all nails implanted by OrthoPediatrics have been the smallest 7mm diameter; the implant is available in 7mm-12mm diameters. PNP Tibia is currently available in five markets, with a European launch planned for 2027. OrthoPediatrics markets over 90 systems exclusively in pediatric orthopedics, distributing in the United States and more than 75 countries.

•1mo ago

OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations

OrthoPediatrics announced the full commercial launch of its 3P Pediatric Plating Platform Hip System after a successful limited launch period. The company reported over 350 surgical implantations prior to full commercialization, validating the clinical utility and demand for the system. This release marks the first product in the broader Pediatric Plating Platform portfolio, designed to offer enhanced fixation options for pediatric trauma and deformity correction.

•2mo ago

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

OrthoPediatrics reported record Q2 revenue of $70.5 million, up 15% year-over-year, driven by a 26% increase in Trauma & Deformity revenue and solid international growth. Adjusted EBITDA more than doubled to $6.8 million, while free cash flow usage was reduced by 78% to $3.1 million compared to the prior year. The company raised its full-year 2026 revenue guidance to $265.0 million-$269.0 million and reiterated its target to achieve cash-flow breakeven in 2026.

•3mo ago

OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide

OrthoPediatrics announced an exclusive distribution agreement with OSSIO to provide the OSSIOfiber bio-integrative fixation technology to children's hospitals across the U.S. The metal-free implants are designed to be replaced by natural bone during the healing process, potentially reducing the need for secondary hardware removal surgeries. Management expects the partnership to expand the company's reach and complement its existing portfolio of pediatric orthopedic solutions.

•4mo ago

OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance

OrthoPediatrics reported Q1 2026 revenue of $59.4 million, up 13% year-over-year, driven by 14% growth in Trauma & Deformity and 22% international growth. Adjusted EBITDA swung to a positive $2.2 million compared to a loss of $0.4 million in the prior year, while free cash flow usage improved by 40%. The company raised its full-year 2026 revenue guidance to $263.0 million-$267.0 million, representing 11-13% growth, and reiterated expectations for $25.0 million in adjusted EBITDA.

•6mo ago

OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System

OrthoPediatrics expanded its Specialty Bracing portfolio with the launch of the TRAXIO Complete - Weight System, a halo gravity traction system for pediatric spinal realignment. The non-active, mechanical traction system was developed in collaboration with Synetik Group and is designed for use in hospital environments. Management noted that TRAXIO extends the continuum of care from bracing through surgery and strengthens the company's position as a comprehensive partner to pediatric spine surgeons.

•6mo ago